慕恩生物

MoonBiotech is a clinical-stage biotechnology company headquartered in Guangzhou, China, focused on the discovery and development of microbial-based therapeutics and agricultural biologicals. The company utilizes its proprietary Culture-to-Product platform, which houses an extensive library of over 200,000 microbial strains, to identify high-value functional microbes and metabolites. Its lead therapeutic candidate, MNC-168, is being evaluated in clinical trials for its ability to enhance the efficacy of anti-PD-1 therapies in patients with solid tumors. MoonBiotech's pipeline also includes programs targeting metabolic disorders, inflammatory diseases, and skin conditions. By integrating high-throughput screening with advanced fermentation technology, the company aims to provide innovative solutions for human health and sustainable agriculture.